@mkonople

Director, Leukemia Program and Co-Director Blood Cancer Institute, Albert Einstein College of Medicine & Montefiore Medical Center, NY | Tweets: my own opinions

Joined July 2013
  • Tweets124
  • Following86
  • Followers624
Marina Konopleva retweeted
Joshua Zeidner MD@LeukDocJZSep 2
We are entering a new frontier in AML ➡️The Paradigm study now out in @NEJM showing improved EFS in younger non-fav. risk AML Tx with Aza/Ven vs. Intensive chemo. Huge congrats to Amir Fathi & all authors for this incredibly important study & milestone. nejm.org/doi/full/10.1056/NE…

Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia | NEJM

Induction chemotherapy has long been a key component of curative therapy for fit patients with acute myeloid leukemia (AML), despite its frequently severe side effects and substantial health care u...

nejm.org
6
36
5
109
17,372
Marina Konopleva retweeted
Naveen Pemmaraju, MD@doctorpemmAug 19
👉👉👉I was truly grateful to be invited to deliver DoCM Grand Rounds today @UTMDAnderson moderated by Dr @vincedcataldo & Dr Bob Wolff! Excellent Q&A discussion after the talk! #BPDCN #RareDisease | @sanamloghavi @mpdrc @harrisoncn1 @DavidFajgenbaum @montypal @Transplant_Doc 🙏
1
6
1
43
1,447
Our Center for the Advancement of Blood Cancer Therapies #CABCT summer gathering on the Hudson. Breathtaking views and great company! So fortunate to work with these amazing talented people. @Elvin_Wag @FrancoIzzo85 @Dr_Sturgeon
1
4
27
1,426
Marina Konopleva retweeted
Naveen Pemmaraju, MD@doctorpemmJul 13
👉Decreased #TXNRD1 is associated with resistance to #tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II | Leukemia | #BPDCN #endcancer nature.com/articles/s41375-0…

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic...

Leukemia - Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II

nature.com
4
8
1,147
Marina Konopleva retweeted
Naveen Pemmaraju, MD@doctorpemmJul 13
Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm ashpublications.org/blood/ar… | #BPDCN #endcancer @lane_andy @LuskinMarlise @ShaiShimony @NitinJainMD @Daver_Leukemia @mkonople @doctorpemm || @BloodPortfolio || @bcutd_research @VJHemOnc @TheIACH

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm

Key Points. TAG-AZA-VEN is effective in both untreated and relapsed BPDCN, with manageable safety including in an elderly patient population.TAG-AZA-VEN is

ashpublications.org
9
32
1,713
Marina Konopleva retweeted
Andy Lane@lane_andyJul 7
Thrilled to share our clinical trial of the TAG-AZA-VEN triplet for #BPDCN published today in Blood @BloodPortfolio. Team effort! New option for patients- important. Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm ashpublications.org/blood/ar…

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm

Key Points. TAG-AZA-VEN is effective in both untreated and relapsed BPDCN, with manageable safety including in an elderly patient population.TAG-AZA-VEN is

ashpublications.org
5
13
57
3,745
Marina Konopleva retweeted
Naveen Pemmaraju, MD@doctorpemmJul 7
👉👉👉Very proud to share our brand new article 📝 just out in @LeukemiaJnl led by own brilliant colleague Dr Hannah Beird .@genesntexas | Novel finding in our #BPDCN field ➡️ decreased #TXNRD1 associated with #tagraxofusp resistance in #BPDCN #endcancer nature.com/articles/s41375-0…
1
2
23
1,458
Marina Konopleva retweeted
Naveen Pemmaraju, MD@doctorpemmMay 27
👉👉👉Breaking News 📰 | Proud to share the wonderful news for our patients & families facing #BPDCN of @US_FDA @FDAOncology approval for #Pivekimab #CD123 for our patients with #BPDCN !🙏| led by @doctorpemm & @Daver_Leukemia | @UTMDAnderson #endcancer fda.gov/drugs/resources-info…
21
40
3
138
26,002
Marina Konopleva retweeted
Iannis Aifantis
@iannisaifantis1Apr 27
that is huge! Congrats to @rosslevinemd @DavidSteensma and the Ajax Therapeutics Team!
The Wall Street Journal
@WSJApr 27
Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer portfolio. on.wsj.com/4vSypnF
3
1
2
59
10,618
Marina Konopleva retweeted
Hagop Kantarjian,MD@DrHKantarjianApr 27
Adding blinatumomab and inotuzumab to hyperCVAD in younger B-cell #ALL improves EFS from 66% to 89% doi.org/10.1002/ajh.70327 @AjHematology @UTMDAnderson
4
24
1
103
6,688
Marina Konopleva retweeted
Keisuke_Ito_Lab@keisuke_ito_labApr 19
Enjoyed the ASCI Dinner & New Member Induction Ceremony—truly an honor and milestone as a physician-scientist. Grateful to join @the_asci and follow in the footsteps of an inspiring group of physician-scientists! @EinsteinMed @Einstein_SCI @MontefioreNYC
1
5
28
1,466
Marina Konopleva retweeted
ESH (Haematology)@ESHaematologyApr 14
📣 DISCOVER THE MAIN SCIENTIFIC TOPICS OF #ESHMICRO2027 6th Scientific Workshop on #Tumour #Microenvironment Feb. 14–16, 2027 in London, UK Chairs: D. Bonnet, @NitinJainMD, @mkonople, D. S. Krause, S. Méndez-Ferrer, K. Yong For more info ➡ bit.ly/3Lw7Ylj #ESHCONFERENCES
3
10
1,018
Marina Konopleva retweeted
Mendel Goldfinger@MendelGoldfing2Apr 7
Improved outcomes in TP53-mutated MDS/AML without added toxicity. Metronomic decitabine /venetoclax.
Haematologica
doi.org/10.3324/haematol.202… @Amitvermamds @aditishasMD @YannisMantz @Saunthararajah @SteidlUli @mkonople @EinsteinMed @MontefioreNYC
6
15
2
66
8,827
Marina Konopleva retweeted
Keisuke_Ito_Lab@keisuke_ito_labMar 13
Replying to @Hema_News @IcahnMountSinai
Congrats to David (@DDSoLab), Eirini (@PapapetrouMDPhD), and the team on how persistent MYC rewires epigenetic landscapes and TF networks, revealing sustained deregulation drives MYC-driven leukemic transformation. @ISEHSociety
7
1
15
2,752
Marina Konopleva retweeted
Daniel Pollyea@DanPollyeaMar 2
pubmed.ncbi.nlm.nih.gov/4174… Excited about the publication of our long-time coming clinical trial, with @JustinWattsMD @UMiamiHealth. We enrolled newly diagnosed AML patients younger than 60, independent of fitness for intensive chemotherapy, and gave them venetoclax.

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for...

Venetoclax (ven) + azacitidine (aza) is the standard of care for newly-diagnosed acute myeloid leukemia (AML) patients who are not candidates for intensive chemotherapy (IC). Because prognostic...

pubmed.ncbi.nlm.nih.gov
2
8
37
2,695
Marina Konopleva retweeted
Wing Fai Li@WFDr19Feb 23
Excited to share our latest review article on TP53-mutated AML/MDS. Heartfelt thanks to our wonderful mentor Dr. Konopleva for her constant support, encouragement, and guidance. @mkonople @AndrewGutwein @jmsongmd @jmcchiefs @shwetad96 frontiersin.org/journals/onc…

Frontiers | TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive...

TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) represent a biologically and clinically distinct subset of myeloid malignancies...

frontiersin.org
2
2
3
13
6,205
Marina Konopleva retweeted
Naveen Pemmaraju, MD@doctorpemmFeb 20
👉👉👉Very pleased to share our group’s new paper, led by Dr .@AP_Singh_MD 📝 just out in Leukemia&Lymphoma ➡️ a milestone in our #BPDCN field : 📣 10 -year + long-term survivors report | #endcancer #leusm #RareDisease @sanamloghavi | @MDAndersonNews tandfonline.com/doi/full/10.…
6
8
3
59
5,033
Marina Konopleva retweeted
Keisuke_Ito_Lab@keisuke_ito_labFeb 18
Honored to contribute to this true team effort led by Samar @Samarpana & Aditi @aditishasMD, including @ae_cancercenter and @nyulangone, translationally examining the clinical target in VEN-resistant AML with a STAT3 degrader, correcting mitochondrial dysregulation. @Cla_Morgant
Hematopoiesis News
@Hema_NewsFeb 18
Dr. Aditi Shastri and team at @MontefioreNYC reveal that a STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia. 📕 @LeukemiaJnl 🔖 go.nature.com/4awWJmx
2
7
28
2,716
Marina Konopleva retweeted
Michael Kharas MSK@KharasLabJan 1
Check out our latest story science.org/doi/10.1126/scie…! Huge thanks to @GauravA_UK and the @bloodgenes lab for driving this work forward together with us. This was a great team effort with outstanding collaborators @_ruslansoldatov, @AbdelWahablab, and @AlexBickMDPhD.

Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation

Somatic mutations that increase the fitness of hematopoietic stem cells (HSCs) drive their expansion in clonal hematopoiesis (CH) and predispose individuals to blood cancers. Population variation in...

science.org
26
42
4
190
20,224
Marina Konopleva retweeted
Naveen Pemmaraju, MD@doctorpemmJan 3
👉👉👉Our multi-center report, our latest #BPDCN collaborative network paper 📝 is now out in L&L, as we aim to continue to raise awareness for our #RareDisease field! #leusm #bmtsm #BPDCN 🙏 | @HemeReports tandfonline.com/doi/full/10.…
3
2
18
1,244
Load more